NCT02120547View on ClinicalTrials.gov

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Liver Insufficiency
Interventions
DRUG

Cenicriviroc in mild liver impaired

Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.

DRUG

Cenicriviroc in moderate liver impaired

Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Inc., Fort Lauderdale

All Listed Sponsors
lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT02120547 - Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter